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1. Introduction 
Idiopathic membranous nephropathy (MN), an autoimmune-mediated glomerulonephritis 
(GN), is one of the most common causes of nephrotic syndrome in adults and may rarely 
lead to idiopathic nephrotic syndrome in childhood (Cattran, 2001; Chadban & Atkins, 2005; 
Ponticelli & Passerini, 1990). The clinical course in the majority of patients appears to be 
indolent and slowly, although some progress into end-stage renal failure. Spontaneous 
remissions of proteinuria occur in approximately one quarter of patients; approximately half 
will have stable renal function with or without persistent proteinuria (Rosen, 1971; 
Wasserstein, 1997). A minority of patients will demonstrate slowly decline in renal function, 
and a few will have rapidly decline leading to renal failure or death. Approximately 30%–
40% of patients with MN develop progressive renal impairment, which results in end-stage 
renal failure after 10–15 years (Cattran, 2001; Chadban & Atkins, 2005; Honkanen et al., 
1992). The etiology in the majority of cases is unknown (idiopathic or primary MN, 75%); 
MN can also be secondary to or associated with a variety of conditions, including systemic 
lupus erythematosus and other autoimmune disorders, chronic infections such as with 
hepatitis B virus, drugs such as penicillamine, and malignant neoplasms (Cattran, 2001; 
Chadban & Atkins, 2005; Honkanen et al., 1992; Ponticelli & Passerini, 1990; Rosen, 1971; 
Wasserstein, 1997). The characteristic finding in MN is the presence of in situ immune-
complex deposition over the subepithelial space which presented with diffuse, discrete, 
granular glomerular capillary wall staining for immunoglobulins and complement on 
immunoflusrescence and subepithelial electron-dense deposits on electron microscopy. The 
deposited immune complexes sequentially induce the inflammatory response, complement 
activation, and oxidative injury, all of which participate in the pathogenesis of MN (Couser 
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& Abrass, 1988; Couser & Nangaku, 2006; Cunningham & Quigg, 2005; Kerjaschki, 2004; 
Nangaku et al., 2005; Ronco & Debiec, 2006).  
However, the role of adaptive immunity in the mediation of glomerular injury in MN has 
not yet been fully elucidated (Couser & Abrass, 1988; Couser & Nangaku, 2006; 
Cunningham & Quigg, 2005; Kerjaschki, 2004; Nangaku et al., 2005; Ronco & Debiec, 
2006). The prominent phenomenon of antigen and antibody immune-complex were 
observed in the process in the Heymann nephritis (HN), one of the most frequently used 
models of human MN in rat (Heymann et al., 1959; Salant et al., 1989). However, recent 
experiments with anti-T cell subset monoclonal antibody (mAb) therapies also suggested 
that T cells are central to the induction and glomerular injury of HN (Quiza et al., 1992). 
Indeed, the immunopathogenesis of MN, especially the role of T cell (including helper 
and cytotoxic T cells), is still not clear (Nangaku & Couser, 2005). The treatment of MN is 
controversial. Controlled trials of corticosteroids with or without cytotoxic or 
immunosuppressive agents have had variable results. Presently available 
immunosuppressive therapies are not always effective and often have many persistent 
side effects (Cattran, 2005; du Buf-Vereijken et al., 2005; Glassock, 2004; Perna et al., 2004; 
Piccoli et al., 1994; Polenakovik & Grcevska, 1999; Ponticelli et al., 1987; Ponticelli, 1987; 
Ponticelli & Passerini, 1991). The treatment of patients with MN is still up for debate. The 
current treatment of this disease remains inadequate and nonspecific. The purpose of this 
review is to bring together current informations concerning the roles of 
immunopathogenesis in the development and progression of MN. Specific emphasis is 
placed on the new murine MN model setup and the kinetics of adaptive immunity during 
MN. In addition, immuno-modulatory treatments using heme oxygenase-1 (HO-1) 
induction in the treatment of MN are also reviewed. 
2. Immunopathogenic mechanism and therapeutic intervention in 
experimental murine model of MN 
2.1 Experimental animal model of MN 
MN is an important cause of nephrotic syndrome and end-stage renal disease in adults. For 
designing more rationale therapy, it would be useful if we really understood basic 
pathophysiology of disease. Since only limited information can be obtained from the direct 
study of diseased humans, animal models are very helpful for us to understand 
pathogenesis. Most results were obtained from HN. However, limited mouse models for 
study of human MN was well-characterized although mice offer the advantages of being 
cheaper, manipulate easily, and suitable for experimental applications. 
2.1.1 Heymann Nephritis (HN) 
HN is a rat model of autoimmune-mediated glomerulonephritis that is similar in 
histopathology to human idiopathic MN (Heymann et al., 1959; HEYMANN et al., 1962). 
In 1959, Heymann et al. (Heymann et al., 1959) first described a model of MN in rats 
induced by immunization with a tissue antigen fraction derived from proximal tubular 
brush borders (Fx1A) in complete Freund’s adjuvant (CFA) (Kerjaschki & Farquhar, 1982; 
Kerjaschki & Farquhar, 1983). This model, subsequently referred to as HN, the 
morphology more closely resembled human MN because the deposits were exclusively 
subepithelial in location(Edgington et al., 1968; Edgington et al., 1967). The “active” HN 
model took several weeks to develop after immunization. Following, passive HN (PHN) 
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model by passively transferring heterologous antibodies to the brush border (anti-Fx1A) 
into normal animals in which antibody deposition induced heavy proteinuria more 
rapidly within only 3 to 4 days, thus finally enabling studies to be conducted of the 
mediation of glomerular injury in MN (Dixon et al., 1961; Van Damme et al., 1978; Fleuren 
et al., 1978). Whether the immune complexes were formed in situ or passive trapping of 
small, soluble immune complexes formed in the circulation is an important issue. Within 
months, Van Damme et al. using ex vivo perfusion system, and Couser et al. using a 
physiologically intact isolated perfused kidney system established that the deposits in 
MN result not from circulating immune complex trapping but from direct, or in situ, 
binding of IgG antibody to native glomerular antigens, presumably expressed on the 
membrane of podocyte foot processes (Van Damme et al., 1978; Couser et al., 1978). The 
nature of the glomerular antigen involving in formation of subepithelial deposits in HN 
was systematically tracked down by Kerjaschki and Farquhar and demonstrated as a 
combination of megalin and a receptor-associated protein (RAP) in the podocyte 
membrane (and tubular brush border) (Kerjaschki & Farquhar, 1982; Makker & Singh, 
1984; Farquhar et al., 1995). Megalin (gp330) has been identified as a pathogenic antigen in 
HN, but it has not been found in human or mice glomeruli. Hence, the precise nature of 
the idiopathic MN-initiating antigen is still unknown. (Ronco & Debiec, 2007b; Ronco & 
Debiec, 2007a; Ronco & Debiec, 2005). 
2.1.2 Murine model of MN induced by cationic bovine serum albumin 
The HN is a generalized model with morphological and functional aspects similar to 
those of human MN. However, it has rarely been applied to the mouse which have 
advantages of low cost, easily manipulation and the potential application of genetic and 
monoclonal antibody techniques (Quigg, 2003). Repeated doses of cationic bovine serum 
albumin (cBSA) are alternative methods to induce MN which had been applied in the dog, 
cat, rabbit and rat (Wright et al., 1985; Nash et al., 1990; Border et al., 1982; Bass et al., 
1990). The purity of the cBSA antigen is an important factor to cause variants of MN. The 
heterogeneity of the antigenic charge distinctly affects its ability to cause damage: the 
more cationic the immunogen, the more nephritogenic it is and the greater its tendency to 
produce a typical MN pattern. Unlike the cBSA preparations previously used only 
characterized by polyacrylamide gel flat bed electrophoresis and fast protein liquid 
chromatography(Bass et al., 1990; Wright et al., 1985), which could not exclude the 
presence of native anionic and slightly cationic BSA, we used pH-dependent binding 
technique to purify a more homogenous cBSA preparation which made our model 
disclosing greater consistency (Chen et al., 2004; Wu et al., 2008a; Yang & Langer, 1985). 
Mice were immunized with 0.2 mg of cBSA emulsified in complete Freund’s adjuvant 
(CFA), two weeks later, these mice received cBSA (13 mg/kg) intravenously three times 
per week, every other day, for six weeks to induce MN. There was a dose-related effect in 
the induction of MN and strain specificity because MN could be induced in BALB/c mice, 
but not in the C57BL/6 strain (Chen et al., 2004; Wu et al., 2008a). All cBSA-induced MN 
mice developed the characteristically clinical symptoms of proteinuria, 
hypoalbuminaemia, and hypercholesterolaemia. The MN induction rate did not differ 
between male and female mice reflecting the equal incidence of MN in men and women. 
Overt proteinuria appeared in week 4 and reached a plateau at week 8. Serum albumin 
concentration declined markedly after week 6 in the MN group and reached its nadir at 
week 8. However, serum cholesterol concentration showed a compensatory increase at 
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week 6 and was maximal at week 8. The above presentations assemble like nephrotic 
syndrome in human MN. The blood urea nitrogen and serum creatinine concentrations 
did not change during MN induction. Urinalysis revealed no haematuria or leukocyturia 
during the study.  
Histological findings revealed characteristically MN morphologic pattern, namely, diffuse 
thickening of the glomerular basement membrane (GBM) and no significant mesangial 
proliferation in light microscopy. (Figure 1A) Ultrastructural analysis identified severely 
irregular thickening of the basement membrane and subepithelial deposits in mice with 
cBSA-induced MN. (Figure 1D) Positive immunofluorescent staining for IgG was noted by 
progressively stronger granular fluorescence intensity along the glomerular capillary wall 
(GCW) with a discrete beaded appearance. Immunofluorescence staining for C3 revealed a 
similar time course and pattern to that of IgG. (Figure 1B and C) Loss of glomerular anions 
and the impairment of charge selectivity were noted evidenced by decreased the intensity of 
colloid iron staining progressively during the course of MN induction. We also found that 
the Th2 response was predominant: IgG1 concentration was significantly higher than IgG2a 
concentration. These data indicate that the MN mouse model is associated with a Th2 
response. An important issue is to determine whether cBSA-induced MN in mice resembles 
the in situ immune-complex glomerulonephritis seen in humans. Immunofluorescence 
analysis revealed positive staining for both IgG and C3. Although a strong positive 
immunofluorescent staining of immune-complex deposition was concomitant with higher 
serum Ig concentrations, serum CIC concentration did not increase significantly before week 
4. These observations suggest the in situ immune-complex formation in cBSA-induced MN, 
although we cannot exclude the possibility that the lower CIC concentration might have 
been generated in the earlier stages but was deposited rapidly in the kidney. Previous 
studies using both in vitro and in vivo approaches have demonstrated that cBSA binds 
directly to the glomerulus and then forms the in situ immune-complex deposition. BSA can 
induce in situ immune-complex formation in the isolated perfused rat kidney (Fleuren et al., 
1980). Antigen quantity also seems to be a cofactor influencing MN induction and a 
threshold exposure to antigen is needed for induction (Breysse et al., 1994)]. Although the 
mechanisms responsible for this variable course remain unclear, our results suggest that 
lower antigen exposure might increase the chance of spontaneous remission. We speculate 
that the antigen source, dose and exposure duration are factors in the pathological and 
clinical diversity of MN.  
We report the development of a new MN mouse model induced by cBSA. Clinically, the 
animals developed hypoalbuminaemia, hypercholesterolaemia and severe proteinuria. 
Morphologically, they exhibited diffuse GBM thickening, granular immunofluorescent 
staining, subepithelial deposits, and a lack of inflammatory cell infiltration and mesangial 
cells proliferation. Exogenous cBSA antigen had a dose-related influence on disease 
induction and may have induced in situ immune-complex GN. Moreover, this mouse MN 
model may display Th2 polarization and strain-specific dependence. Extending the MN 
model to the mouse has the advantages of lower cost, easy manipulation, and the 
potential benefits of using gene knockout and transgenic mice to investigate the 
mechanisms of disease initiation and progression. Thus, this model exhibits great 
similarity to human MN disease in clinical and pathological features over time. This 
murine model will provide a valuable tool to investigate the pathogenesis of MN and will 
help in the development of preventive and therapeutic strategies for MN, which is 
difficult to study in humans. 
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Fig. 1. Renal histopathology in mice with MN. Histopathology revealed characteristic 
findings of diffuse basement membrane thickening, as observed in the (A) hematoxylin and 
eosin staining, (B) positive granular immunofluorescent staining for IgG,  (C) positive 
granular immunofluorescent staining for C3, and (D) subepithelial deposition (asterisk). NC, 
normal control; MN, membranous nephropathy; G, glomerular basement membrane; L, 
lumen of capillary; and U, urinary space. 
2.2 Immunopathogenesis of cBSA-induced MN 
MN has been recognized as an autoimmune-mediated GN and characterized by an in situ 
immune-complex disposition over the subepithelial space which caused physical disruption 
of the filtration barrier and triggered a cascade of events that contribute to the progression 
of the disease and result in glomerular injury and proteinuria (Ravnskov, 1998; Ronco & 
Debiec, 2005). The C-BSA binding to glomerular tuft anion site, then immunoglobulin and 
complement will be produced and aggregated to GBM and mesangial area. This results in 
glomerular epithelial cell injury and proteinuria in our cBSA-induced murine MN model. 
Mediation of glomerular injury in MN has been thought to be essentially leukocyte 
independent (Salant et al., 1985). Early studies using monoclonal antibodies to T cell subsets 
indicate that T cells are central to the induction and glomerular injury in HN, a rat model of 
idiopathic MN (Penny et al., 1997; Penny et al., 1998; Quiza et al., 1992). The T lymphocyte-
derived cytokines also regulate the cellular and humoral immune responses to 
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nephritogenic antigens and modulate inflammatory events (Holdsworth et al., 1999; Kelly et 
al., 1998). However, the role of adaptive immunity in the mediation of glomerular injury in 
MN has not yet been fully elucidated.  
2.2.1 The role of T cells and their cytokines in MN 
It is widely recognized that CD4+ T cells can be differentiated into two subsets, Th1 and Th2, 
according to their cytokine profiles (Abbas et al., 1996; Mosmann & Sad, 1996). Th1 cells 
produce cytokines such as interleukin (IL) 2, interferon γ IFN-γ, and tumor necrosis factor 
α TNF-αto promote cell-mediated immunity. Th2 cells producing IL-4, IL-5, IL-10 and IL-13 
can suppress Th1 cell activation and contribute to humoral immunity(Mosmann & Coffman, 
1989). Th1 and Th2 subsets are regulated reciprocally to maintain a balance, which plays an 
important role in immune-mediated GN (Tipping & Kitching, 2005). Th1 and Th2 subsets 
direct diverging effector pathways and lead to different patterns of injury and outcomes in 
GN. Th1-predominant responses are strongly associated with proliferative and crescentic 
forms of GN while Th2 responses are associated with membranous patterns of injury 
(Schena, 1999; Ring & Lakkis, 1998). To our knowledge, the diversity of Th1/Th2 in MN is 
still controversial. Studies involving patients with idiopathic MN showed a consistently 
negative response for delay type hypersensitivity (DTH) effectors, an increase in IL-4 
production by peripheral T helper cells; and a predominance of IgG4 (Th2-type subclass) as 
well as complement deposition in glomeruli; suggesting a Th2 response (Oliveira, 1998; 
Kuroki et al., 2005; Masutani et al., 2004; Hirayama et al., 2002; Doi et al., 1984; Doi et al., 
1991; Haas, 1994; Imai et al., 1997; Iskandar et al., 1992; Roberts et al., 1983). The above 
findings favor Th2 response. However, Penny et al found that the progressive development 
of infiltrates of activated T cells—principally Th1 and cytotoxic effector cells—as well as 
macrophages identified within glomeruli of Lews rats with HN, coincides with the 
development of proteinuria (Penny et al., 1998). Early studies suggested that classical T cell 
effector responses are involved in HN, including passive transfer of HN to tolerant rats by 
lymphoid cells but not serum, and lymphoid cells in culture(Heymann et al., 1962; Hsieh et 
al., 2000). Furthermore, it has also been found that permanent CD8+ T cell depletion both 
early and late in the course of disease prevents proteinuria in active Heymann Nephritis. It 
may indicate that CD8+ cytotoxic T cells are essential to the mediation of glomerular injury 
in HN and may be relevant to the pathogenesis of MN (Penny et al., 1998). In addition,, 
Spicer et al found that IL-4 administration prior to the onset of protienuria, rather than the 
early rIL-4 treatment prevents the development of proteinuria in active Heymann Nephritis 
by inhibition of Tc1 cells (Spicer et al., 2001). All these results indicate the importance of 
CD8+ T cell in mediating the final effector phase of glomerular injury in HN (Penny et al., 
1998; Spicer et al. 2001) and suggest that Th1 cells participate in the glomerular injury and 
proteinuria of MN (Penny et al., 1997).The conclusion of the diversity of Th1/Th2 in MN are 
not consistent. 
2.2.2 The kinetics of adaptive immunity of cBSA-induced in MN 
The kinetic distribution of different lymphocyte subsets, as well as the association between 
clinical manifestations and the complicated course of adaptive immune responses during 
MN is not well understood. To directly investigate immunoregulatory process and 
immunopathological mechanisms in cBSA-induced MN, we used TH1/TH2 double 
transgenic mouse (T1/T2 TG mice) which provides the best in vivo model to study the 
differentiation of helper T cell subsets during the Th process was used (Wu et al., 2007). 
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T1/T2 TG mice, originally in BALB/c background, bear two transgenes expressing two 
distinct cell surface markers, one is human Thy1 protein (human CD90) under the murine 
IFNγ promoter control, the other is murine Thy1.1 protein (murine CD90.1) under the 
murine IL-4 promoter control, designated as TH1/TH2 transgenes respectively(Hsieh et al., 
2000; Hung et al., 2005). 
T1/T2 TG MN mice showed overt proteinuria, hypoalbuminemia, and hypercholesterolemia 
characteristically. Renal histopathology revealed typical morphology of MN as glomerular 
basement membrane thickening, IgG granular deposition and subepithelial deposits seen in H 
& E, IF and EM sections. There were no significant differences between the MN mice of the 
BALB/c strain and the T1/T2 TG mice. The numbers of splenic lymphocytes increased 
progressively. The absolute numbers of CD4+ and CD8+ T cells showed reciprocal increased as 
total splenocytes despite relative consistent proportion. A progressive increase in the 
proportion and absolute numbers of CD19+ B cells in the MN mice from week 2; this peaked at 
week 4 and persistent high throughout the MN process were also observed. Two weeks after 
immunization, the MN mice had a significant increase in splenic Th2 cells. This indicates an 
extended Th2 response at this point. We also noticed a trend of increase in the percentage of 
Th1 cells and most of the remaining Th1+ cells is CD8+ T cells. The percentage of DX5+ cells, a 
marker for NK cell, in the MN mice did not differ from that in the controls and there were very 
few cells expressing hCD90 and DX5 markers simultaneously which suggested that most of 
the Th1+ cells were T lymphocytes, but not IFN-γ producing NK cells. The expression levels of 
Th1 and Th2 cells among peripheral mononuclear blood cells from MN mice showed similar 
results. Whether what happening with the T cells in the spleen is also happening in the 
kidneys, we checked the expression of Th1/Th2 reporter in the kidneys by using quantitative 
RT-PCR at various time points. The Th1 reporter/Th2 reporter status of kidney revealed 
parallel changes with those in the spleen. Taken together, these results imply a progressive 
Th2 prone process of adaptive immunity during experimental MN. We also performed 
imunohistochemical staining for hCD90, mCD90.1 and CD4 in the kidneys to identify and 
localize the T-helper cells. The numbers of CD4+ cells were very scanty in NC kidney and the 
numbers were increased in MN kidney. In contrast to hCD90, there were no mCD90.1+ cells 
noted in NC kidney, but prominent mCD90.1+ cells were noted in MN mice. The prominent 
and parallel expression between the mCD90.1+ and CD4+ cells may imply the Th2 polarization 
in renal T cell during MN. 
The Th1 and Th2 subsets can be differentiated according to the production of individual 
cytokines, Th1 regulates Ig switching to the IgG2a subtype, whereas Th2 enhances IgG1 
secretion. We found that the titers of anti-cBSA immunoglobulins—mostly IgG1—increased 
from week 2 and peaked at week 4. Serum level of immunoglobulins at week 6 and week 8 
were lower than those at week 4. These findings may imply the development of tolerance 
and a Th2-predominant response. We further performed the immunofluorescent staining to 
investigate whether the isotype of antibodies deposited in the kidney parallels to the 
findings in sera, and the result revealed a prominent IgG1 antibody deposition in the kidney 
rather than IgG2a. A progressive increase in the proportion and absolute numbers of CD19+ 
B cells in the MN mice during the early phase of MN combined with the production and 
deposition of IgG1 predominant anti-cBSA immunoglobulin in the serum and kidneys 
indicate that the initial immune response primarily involves the humoral-mediated 
mechanism. Recent studies have demonstrated that blocking the CD20-positive B cells by 
rituximab, and thereby, inhibiting B-cell differentiation and immunoglobulin secretion, can 
reduce proteinuria and prevent disease progression in patients with idiopathic MN. This 
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further confirms the pathogenic role of B cells in MN (Cohen et al., 2005; Remuzzi et al., 
2002; Ruggenenti et al., 2003). In our previous study, the cBSA-induced MN can be induced 
in Th2-prone BALB/c mice, but not in Th1-prone C57BL/6 mice(Chen et al., 2004). In this 
study, we further showed that the Th2 CD4+ response, and not the Th1 CD4+ response, 
significantly correlated with the progression of MN. All the results confirmed the relevant 
role of B cells participating in the process of MN. 
We further investigated the secretion of IFN-γ and IL-4 from splenocytes to confirme 
whether cBSA is a specific antigen in this MN model by using antigen-specific stimulation 
test stimulated with or without cBSA. As compared to NC mice, levels of IL-4 were 
increased significantly in MN mice and cBSA restimulation may further enhance its 
secretion. We identified a significant increase in IL-4 producing cells in the MN group 
without specific antigen re-stimulation. However, Th1 cells were only slightly amplified. 
Interestingly, lymphocyte subsets from the MN group re-stimulated with specific antigens 
displayed a greater capacity to secrete IFN-γ and IL-4, especially among the IFN-γ-
producing CD8+ T cells and IL-4-producing CD19+ B cells. Nevertheless, CD8+ T cells 
contributed more to the augmented production of IFN-γ than did CD4+ T cells; moreover, 
CD19+ B cells also demonstrated greater IL-4 production than the CD4+ T cells. Quantitative 
real-time PCR of renal cortex and splenocytes demonstrated a consistent change with 
slightly increased expression of proinflammatory (TNF-α and IL-6) and Th1 cytokines (IL-2, 
IFN-γ) and extremely high expression of Th2 (IL-4 and IL-10) cytokines. Finally, we found 
that the Th2 CD4+ response increased as the MN progression and showed that the number 
of Th2 cell not the Th1 cell significant correlated with serum cholesterol and proteinuria. 
In the MN mice, production via cBSA re-stimulation and subsequent staining of intracellular 
cytokines from cultured splenocytes revealed a significant increase in IL-4-producing CD4+ 
T cells, but only a slight increase in IFN-γ-producing CD4+ T cells. This provides further 
evidence confirming the maintenance of Th2 cells post cBSA induction. Furthermore, data 
from intracellular cytokines post Ag-specific re-stimulation suggests that IFN-γ is secreted 
predominantly by CD8+ T cells, while IL-4 is secreted by either CD4+ T cells or B cells. These 
results may imply that CD4+ T cells preserve their potential Th2 capacity after MN and that 
CD8+ T cells function more effectively than CD4+ T cells in the production of IFN-γ 
following re-exposure to antigens. In addition to assisting in antibody production, the T 
helper cell subsets also affect and direct cellular immune mechanisms in GN(Holdsworth et 
al. 1999). Interestingly, we found a latter increase in Th1 expression. The activation of CD8+ 
T cells appears to be much slower than that of the CD4+ T cell-dependent B cell response to 
cBSA. Previous studies have demonstrated that persistent depletion of CD8+ T cell both 
early and late in the course of disease prevented the development of proteinuria. In 
addition, it was also found that IL-4 administration prior to the onset of protienuria, rather 
than the early rIL-4 treatment prevented protienuria in HN, indicating the importance of 
CD8+ T cell in mediating the final effector phase of glomerular injury in HN(Penny et al., 
1998; Spicer et al., 2001). This increase in Th1 cells may play a role in the counter-regulation 
of the Th2 response and implies an association between the characteristics of the disease 
process and the kinetics of the Th1/Th2 responses during MN. Taken together, these 
findings support that the functional dichotomy between the Th1 and Th2 lymphocyte 
subsets play a regulatory role in the disease and both the humoral and cell mediated 
immune responses may participate in the pathogenesis of MN. 
T1/T2 TG mice still has advantages of stable and stronger signal expression, a wider time 
window for detection, lack of requirement of restimulation or permeabilization, and 
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possible isolation of viable cells of given Th phenotypes. Thus, these T1/T2 TG mice are 
useful in providing a feasible and direct in vivo monitoring system for dissecting the changes 
in proportions of pathogenic T cells during the pathogenic or therapeutic processes using 
flow cytometry with surface immunofluorescent staining(Hsieh et al., 2000; Hung et al., 
2005; Sung et al., 2004). 
A progressive increase in Th2 cells were observed in splenocytes as well as in peripheral 
blood and kidney cells. In addition, the Th2 prone IgG1 immunoglobulin subclass was also 
noted in the serum and kidneys. Antigen-specific re-stimulation testing of cytokine 
production and intracellular cytokine staining revealed an IL-4 prominent immune 
response. Cytokine-related gene expression in the kidneys and splenocytes demonstrated 
enhancement of pro-inflammatory cytokines as well as Th1/Th2 cytokines. In conclusion, 
our data demonstrates that both peripheral and renal immune responses are strongly 
polarized toward the Th2 type immune response in the process of cBSA-induced MN. The 
T1/T2 double transgenic mice could provide an available model to dissect the complex 
kinetic changes of adaptive immunity in GN and promises a potential strategy for the 
development of immunotherapeutic strategies against MN in the future. 
2.3 Immunomodulatory treatment using HO-1 induction for cBSA-induced MN 
The central pathogenesis participating in MN involves the formation of subepithelial 
immune deposits and the subsequent production of glomerular injury through complement-
dependent processes, oxidative stress, and inflammatory cytokines, resulting in the 
development of massive proteinuria (Nangaku et al. 2005). However, the appropriate 
treatment of patients with MN is still open to debate. Recently, HO-1 has been noted to have 
biological effects for protective and therapeutic use (Ryter et al., 2006; Kirkby & Adin, 2006). 
On the other hand, presently available immunosuppressive therapies are not always 
effective and often have many persistent side effects (Glassock, 2004). Therefore, whether 
HO-1 induction could be applied in MN treatment was discussed. 
2.3.1 Heme oxygenase-1 
Heme oxygenase (HO) is the rate-limiting enzyme that degrades heme into carbon 
monoxide (CO), ferritin, and biliverdin (Tracz et al., 2007a). Three distinct HO enzymes 
have been identified: HO-1, HO-2, and HO-3. The HO-1 identified as an enzyme in 
microsomes and was described as a new member of the cytochrome p450 family and later 
found to be a rapidly and transiently inducible mono-oxygenase. The inducible HO-1 is 
expressed in response to various stimuli, such as hydrogen peroxide, heat, heavy metal ions, 
hyperoxide, endotoxin, and inflammatory cytokines, whereas another isoenzyme of HO, 
HO-2, is constitutively expressed and abundant in testes, brain, liver and vasculature. HO-1 
has been shown to have cytoprotective properties, as well as anti-inflammatory, anti-
oxidant, anti-apoptotic, and possible immunomodulatory functions (Ryter et al., 2006; 
Kirkby & Adin, 2006; Nath, 2006). Using chemical inducers or genes, HO-1 has been shown 
to be expressed in various diseases, including respiratory diseases, cardiovascular diseases, 
renal disease, ocular diseases, liver injury and organ transplantation in animal models 
(Abraham & Kappas, 2005; Agarwal & Nick, 2000). 
2.3.2 HO-1 induction for MN treatment 
MN mice receiving HO-1 inducer, cobalt protoporphyrin (CoPP), treatment revealed a 
marked attenuation of proteinuria, hypoalbuminaemia and hypercholesterolaemia (Wu et 
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al., 2008b). However, HO-1 inhibitor, tin protoporphyrin (SnPP), treatment did not have 
such therapeutic effects. The pathological severities of the kidney from MN mice receiving 
CoPP (MN-CoPP) were milder than those from the MN and MN receiving SnPP mice (MN-
SnPP). All these three experimental groups showed positive immunofluorescent staining for 
IgG, with a discrete beaded appearance, along the glomerular capillary wall, but the 
immunofluorescence intensity in the MN-CoPP mice was lower than that in the MN-SnPP 
and MN mice. Immunofluorescent staining for C3 also presented as intense granular 
fluorescence along the glomerular capillary wall, with a similar pattern to that of IgG. Next, 
we checked the serum levels of anti-cBSA antibodies in mice to investigate whether the 
induction of HO-1 modulates the production of the immunoglobulins, causing the 
subsequent decrease in the immunofluorescence intensity of IgG and C3 during the course 
of experimental MN. Significantly elevated the levels of serum anti-cBSA antibodies were 
observed in the MN, MN-CoPP, and MN-SnPP groups compared with those of the control 
groups. Compared with control MN mice, CoPP treatment inhibited and SnPP treatment 
enhanced the production of immunoglobulins during MN course.  
Oxidative stress plays an important pathogenic role in MN. We further assessed whether 
CoPP or SnPP treatment modulates the production of oxidative stress systemically in the 
serum and locally in kidneys. We checked the lipid peroxidation products, thiobarbituric 
acid reactive substances (TBARS), as markers of oxidative stress. The serum TBARS levels in 
MN mice were significantly higher than those in NC mice. CoPP treatment effectively 
attenuated the levels of TBARS to a level similar to that observed in NC mice. However, 
SnPP, which inhibits HO-1, did not reduce the level of oxidative stress, as indicated by the 
higher levels of serum TBARS observed in MN mice treated with SnPP. TBARS in the 
kidney displayed a similar pattern to that observed in serum. These findings suggest that 
HO-1 reciprocally affects both local and systemic oxidative stress. We also analyze in situ 
superoxide anion radical production by using DHE assay in fresh-frozen sections of renal 
tissue to more specifically and locally detect the ROS production in the kidney which 
revealed similar results as TBARS. Anti-apoptosis effect is another major cytoprotective 
function of HO-1. We then checked whether HO-1 induction alleviates cell apoptosis in MN. 
There were nearly undetectable TUNEL-positive cells, as an index of cell apoptosis, in 
normal mouse kidneys. However, increased numbers of apoptotic cells were detected in the 
glomeruli and surrounding tubules of MN mice. Compared with MN mice, little apoptosis 
was observed after MN mice were treated with CoPP, as indicated by a decrease in the 
number of TUNEL-positive nuclei. The administration of SnPP failed to reduce the 
apoptosis in kidney cells. Therefore, the anti-apoptotic effect induced by CoPP may also 
contribute to the therapeutic effect of HO-1 in MN mice.  
In addition to its anti-oxidative and anti-apoptotic properties, HO-1 also displays well 
documented anti-inflammatory activity. We examined the mRNA expression of 
inflammation-associated cytokines in the renal cortex to answer the question of whether the 
induction of HO-1 modulates the inflammatory state. The expression of pro-inflammatory 
cytokines (IL-1 and TNF-α), Th1 cytokines (IFN- and IL-2), Th2 cytokines (IL-4 and IL-10), 
the fibrogenic cytokine transforming growth factor (TGF) , and HO-1 were checked. 
Quantitative real-time PCR of the renal cortex demonstrated a consistent change in MN, 
with an increased expression of pro-inflammatory, Th1 cytokines and Th2 cytokines. CoPP 
treatment dramatically induced HO-1 expression in the kidneys, decreased the level of pro-
inflammatory cytokines (IL-1 and TNF-), and extremely increased the level of anti-
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inflammatory cytokine IL-10. SnPP also decreased the pro-inflammatory cytokines, but did 
not induce the anti-inflammatory cytokine IL-10. 
Previous studies demonstrated that oxygen radical scavengers can dramatically reduce 
proteinuria in HN (Neale et al., 1994). In our study, MN mice treated with CoPP showed a 
dramatic reduction in the generation of highly reactive compounds of lipid peroxidation 
products, TBARS, and in proteinuria. These results indicate that oxidative stress may play a 
pathogenic role in damaging the glomerular filtration barrier, and could be causally related to 
proteinuria in experimental MN (Nangaku et al., 2005). The decrease in TUNEL-positive 
kidney cells after CoPP treatment observed in our study also demonstrates the anti-apoptotic 
properities of HO-1 (Ryter et al., 2006; Nath, 2006). The metabolic derivatives of heme 
produced by HO-1 (CO and biliverdin) have powerful anti-apoptotic and anti-oxidative 
properties. Whether the cytoprotective capacity of HO-1 in experimental MN is exerted via 
these byproducts requires further investigation. However, there was no prominent infiltration 
of inflammatory cells in our murine MN model. Therefore, we speculate that the resident 
kidney cells contribute to the induction of HO-1. Renal vascular and tubular structures express 
HO-1, particularly in response to injurious conditions (Abraham & Kappas, 2005). Glomeruli 
have also been reported to express HO-1 in the human kidney in various renal diseases 
(Morimoto et al., 2001). It seems that site-specific expression along the nephron or in the 
interstitium occurs due to the proximity of the stimulus. In our study, it was difficult to clarify 
whether the protective effect of HO-1 was mediated through systemic or local action, because 
both effects coexisted when the mice received CoPP treatment. Previous studies using either 
the exogenous administration of HO-1 by gene transfer specifically expressed in the kidney or 
chemical induction or transgenic mice, all demonstrated the therapeutic effects of HO-1 in 
different disease models (Kirkby & Adin, 2006; Agarwal & Nick, 2000). Therefore, we assume 
that both the systemic immunomodulatory effect, which decreases the production of 
immunoglobulins and subsequently or directly reduces inflammation, complement activation, 
oxidative stress, and apoptosis, and the local effect in the MN glomeruli contribute to the 
therapeutic effect of HO-1. 
The HO-1 induction caused the effective attenuation of proteinuria via multiple 
mechanisms, including immunomodulatory, anti-oxidative, and anti-apoptotic effects. 
(Figure 2) CoPP-induced HO-1 suppressed the synthesis of pro-inflammatory cytokines 
such as IL-1, IFN- and TNF-. Furthermore, it stimulated the production of the anti-
inflammatory cytokine, IL-10. It has been postulated that the degradation products of heme 
and its metabolic derivatives (CO in particular) might contribute to the anti-inflammatory 
functions of HO-1. The CO-mediated anti-inflammatory effect caused by the increasing 
production of IL-10 and the inhibition of TNF- and IL-1 has been reported to be mediated 
through interactions with the MAPK signaling pathways (Ryter et al., 2006). In contrast, IL-
10 mediates the immunosuppressive effect by an HO-1-dependent pathway (Lee & Chau, 
2002). CoPP treatment also significantly reduced the production of serum anti-cBSA 
antibodies and glomerular immunodeposits in experimental MN mice. It has been 
demonstrated that the immunomodulatory effect of HO-1 is associated with regulatory T-
cell Foxp3 expression and T-cell proliferation via IL-2 (Brusko et al., 2005; Pae et al., 2004). 
However, the role of HO-1 in the reduction of immunoglobulin production remained 
unclear. The direct action of induced HO-1 against systemic inflammation, the concomitant 
decrease in the production of immunoglobulins, together with the subsequent decrease in 
immunodeposition, and other factors such as complement activation and inflammation, 
may all contribute to the attenuation of proteinuria. In our study, both CoPP and SnPP 
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decreased the pro-inflammatory cytokines, but only CoPP increased the production of the 
anti-inflammatory cytokine IL-10. Apart from the regulation of pro-inflammatory and anti-
inflammatory cytokines, CoPP also decreased the level of immunoglobulin production, 
complement activation, and oxidative stress, which have been proposed to be major 
pathogenic factors in MN. This may partially explain why only CoPP, and not SnPP, exerted 
a therapeutic effect in alleviating experimental MN in our study. In contrast, the deficiency 
of HO-1 impairs renal hemodynamics and exaggerates systemic inflammatory response in 
mice (Tracz et al., 2007c; Tracz et al., 2007b). 
 
 
Fig. 2. Cytoprotection by HO-1 in experimental MN. HO-1 induction therapy decreased 
immunoglobulin production and subsequently or directly attenuated inflammation, 
complement activation, oxidative stress, and apoptosis in MN glomeruli, all of which 
contributed to the amelioration of disease severity in MN mice. End, glomerular endothelial 
cell; Epi, glomerular epithelial cell; GBM, glomerular basement membrane; MC, mesangial 
cell. 
The development of ideal therapeutic agents that can effectively and specifically blunt the 
pathogenic pathway in MN is an important issue. This is the first study to demonstrate that 
the endogenous induction of HO-1 significantly ameliorates proteinuria and the severity of 
pathology in MN mice. The induction of HO-1 suppressed the production and deposition of 
immune complexes in the kidney. Both systemic and local oxidative stresses were reduced 
in the sera and kidneys of CoPP-treated MN mice compared with those of MN mice or 
SnPP-treated MN mice. Apoptosis in the kidney cells was also reduced after treatment with 
CoPP. Conversely, decreased pro-inflammatory cytokine expression and increased anti-
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inflammatory cytokine expression were observed in the kidneys after treatment with CoPP. 
The efficient administration of CoPP once weekly, which can significantly block the key 
inflammatory, oxidative, and immunomodulatory pathogenesis pathways of MN, make 
HO-1-inducing therapeutic regimens a plausible new option for future therapeutic 
interventions in MN. However, there are still no drugs available that have been specifically 
developed to induce HO-1 and can be applied to human clinical use. Although the 
therapeutic effects of HO-1 have been demonstrated in several diseases in animal models, 
including our experimental MN model, whether it can be applied to humans requires 
further investigation. 
Our results suggest that HO-1 induction therapy ameliorates experimental MN via multiple 
pathways, including anti-oxidative, anti-apoptotic, and immunomodulatory effects. HO-1-
inducing regimens will probably be considered a new therapeutic intervention for MN in 
the future. 
3. Conclusion 
Murine model of MN induced by cBSA exhibited great similarity in clinical and pathological 
features to human MN disease. This murine model will provide a valuable means to 
investigate the pathogenesis of MN and will help in the development of preventive and 
therapeutic strategies for MN. Both peripheral and renal immune responses are strongly 
polarized toward the Th2 type immune response in the process of cBSA-induced MN. The 
T1/T2 double transgenic mice could provide an available model to dissect the complex 
kinetic changes of adaptive immunity in GN and promises a potential strategy for the 
development of immunotherapeutic strategies against MN in the future. Finally, HO-1 
induction therapy ameliorates experimental MN via multiple pathways, including anti-
oxidative, anti-apoptotic, and immunomodulatory effects. HO-1-inducing regimens will 
probably be considered a new therapeutic intervention for MN in the future. 
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